

# Richard S Kaplan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2485678/richard-s-kaplan-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172  
papers

28,731  
citations

52  
h-index

169  
g-index

183  
ext. papers

32,145  
ext. citations

8.7  
avg, IF

6.19  
L-index

#	Paper	IF	Citations
172	Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer.. <i>Clinical Trials</i> , <b>2022</b> , 174077452211069879	2.2	1
171	Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience.. <i>European Urology</i> , <b>2022</b> ,	10.2	3
170	Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer 10 years.. <i>European Journal of Cancer</i> , <b>2022</b> , 163, 1-15	7.5	0
169	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101090	2.2	0
168	Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101199	2.3	1
167	Uptake of the multi-arm multi-stage (MAMS) adaptive platform approach: a trial-registry review of late-phase randomised clinical trials.. <i>BMJ Open</i> , <b>2022</b> , 12, e055615	3	0
166	A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients. <i>European Journal of Cancer</i> , <b>2021</b> , 159, 247-258	7.5	1
165	BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 1386-1395	9.7	3
164	Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 1120-1128	6.2	2
163	MRI and targeted biopsies compared to transperineal mapping biopsies for targeted ablation in recurrent prostate cancer after radiotherapy: Primary outcomes of the FORECAST trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 5009-5009	2.2	0
162	Outcomes of the RAFT trial: robotic surgery after focal therapy. <i>BJU International</i> , <b>2021</b> , 128, 504-510	5.6	3
161	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	2
160	Focal HIFU therapy for anterior compared to posterior prostate cancer lesions. <i>World Journal of Urology</i> , <b>2021</b> , 39, 1115-1119	4	8
159	In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 288-300	12.9	1
158	False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS. <i>European Urology</i> , <b>2021</b> , 79, 20-29	10.2	3
157	Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer. <i>European Urology Focus</i> , <b>2021</b> , 7, 301-308	5.1	3
156	Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 1713-1722	7.5	2

155	Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 99, 102226	14.4	5
154	Inhibition of WEE1 Is Effective in - and -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3705-3715	2.2	11
153	Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3693-3704	2.2	5
152	Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 549-556	11.6	30
151	What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort. <i>European Urology</i> , <b>2020</b> , 78, 163-170	10.2	28
150	Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , <b>2020</b> , 21, 969-977	21.7	13
149	Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry. <i>BJU International</i> , <b>2020</b> , 125, 853-860	5.6	9
148	Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma. <i>Kidney Cancer</i> , <b>2020</b> , 4, 185-195	0.6	
147	Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial. <i>Journal of Urology</i> , <b>2020</b> , 203, 100-107	2.5	4
146	Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound. <i>Journal of Urology</i> , <b>2020</b> , 203, 734-742	2.5	16
145	HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial. <i>Journal of the National Cancer Institute</i> , <b>2020</b> , 112, 944-954	9.7	7
144	Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants. <i>European Journal of Cancer</i> , <b>2020</b> , 124, 56-63	7.5	4
143	The Urological Stethoscope: an essential aide for the modern benign prostatic hyperplasia specialist?. <i>BJU International</i> , <b>2020</b> , 125, 632-633	5.6	3
142	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4064-4075	2.2	25
141	Rezum water vapour therapy: promising early outcomes from the first UK series. <i>BJU International</i> , <b>2020</b> , 126, 557-558	5.6	11
140	A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists. <i>Scientific Reports</i> , <b>2020</b> , 10, 17177	4.9	1
139	Progression-free survival in the ICON8 trial - AuthorsPreply. <i>Lancet, The</i> , <b>2020</b> , 396, 757	40	0
138	Additional Value of Dynamic Contrast-enhanced Sequences in Multiparametric Prostate Magnetic Resonance Imaging: Data from the PROMIS Study. <i>European Urology</i> , <b>2020</b> , 78, 503-511	10.2	16

137	An Exploratory Study of Dose Escalation Standard Focal High-Intensity Focused Ultrasound for Treating Nonmetastatic Prostate Cancer. <i>Journal of Endourology</i> , <b>2020</b> , 34, 641-646	2.7	2
136	Focal High-intensity Focussed Ultrasound Partial Gland Ablation for the Treatment of Localised Prostate Cancer: A Report of Medium-term Outcomes From a Single-center in the United Kingdom. <i>Urology</i> , <b>2019</b> , 133, 175-181	1.6	12
135	Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. <i>Lancet Infectious Diseases</i> , <b>2019</b> , 19, 253-264	25.5	65
134	Mind the gap? The platform trial as a working environment. <i>Trials</i> , <b>2019</b> , 20, 297	2.8	21
133	High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum. <i>Cancer</i> , <b>2019</b> , 125, 2772-2781	6.4	11
132	This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. <i>Trials</i> , <b>2019</b> , 20, 264	2.8	31
131	Association analyses identify 31 new risk loci for colorectal cancer susceptibility. <i>Nature Communications</i> , <b>2019</b> , 10, 2154	17.4	81
130	HIV prevalence and determinants of loss-to-follow-up in adolescents and young adults with tuberculosis in Cape Town. <i>PLoS ONE</i> , <b>2019</b> , 14, e0210937	3.7	20
129	Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application. <i>Clinical Trials</i> , <b>2019</b> , 16, 502-511	2.2	6
128	Metformin use and risk of cancer in patients with type 2 diabetes: a cohort study of primary care records using inverse probability weighting of marginal structural models. <i>International Journal of Epidemiology</i> , <b>2019</b> , 48, 527-537	7.8	18
127	Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. <i>BJU International</i> , <b>2019</b> , 124, 431-440	5.6	48
126	Weekly dose-dense chemotherapy in first-line epithelial ovarian, Fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. <i>Lancet</i> , <b>2019</b> , 394, 2084-2095	40	88
125	AUTHOR REPLY. <i>Urology</i> , <b>2019</b> , 133, 179-180	1.6	
124	Comparing significant prostate cancer detection rates after the introduction of pre-biopsy MRI: turning PROMIS into action. <i>Journal of Clinical Urology</i> , <b>2019</b> , 12, 341-346	0.2	1
123	Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 535-544	11.6	84
122	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet</i> , <b>2019</b> , 394, 143-155	40	175
121	Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , <b>2019</b> , 152, 53-60	4.9	26
120	Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. <i>European Urology</i> , <b>2019</b> , 76, 98-105	10.2	63

119	Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 828-836	9.7	4
118	Re: Jochen Walz. The "PROMIS" of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis? <i>Eur Urol</i> 2018;73:31-2. <i>European Urology</i> , <b>2018</b> , 73, e151-e152	10.2	
117	Patients Preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?. <i>Annals of Oncology</i> , <b>2018</b> , 29, 370-376	10.3	11
116	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1767-1777	59.2	1250
115	Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). <i>European Urology</i> , <b>2018</b> , 73, 23-30	10.2	105
114	Development and internal validation of prediction models for biochemical failure and composite failure after focal salvage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient prognoses. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 26, 13-18	2.8	9
113	Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci. <i>International Journal of Cancer</i> , <b>2018</b> , 142, 540-546	7.5	21
112	Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. <i>European Journal of Cancer</i> , <b>2018</b> , 102, 31-39	7.5	14
111	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. <i>Health Technology Assessment</i> , <b>2018</b> , 22, 1-176	4.4	46
110	Resistance to first-line ART and a role for dolutegravir. <i>Lancet HIV</i> , <b>2018</b> , 5, e112-e113	7.8	3
109	Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 162-171	18.8	37
108	Role for Nucleotide Excision Repair Gene Variants in Oxaliplatin-Induced Peripheral Neuropathy.. <i>JCO Precision Oncology</i> , <b>2018</b> , 2, 1-18	3.6	
107	What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators Preferences in the SORCE Trial. <i>Kidney Cancer</i> , <b>2018</b> , 2, 123-131	0.6	3
106	A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. <i>European Urology</i> , <b>2018</b> , 74, 422-429	10.2	122
105	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , <b>2018</b> , 100, 35-45	7.5	20
104	Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. <i>Lancet, The</i> , <b>2017</b> , 389, 815-822	40	1485
103	Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab. <i>Journal of Medical Genetics</i> , <b>2017</b> , 54, 567-571	5.8	2
102	Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3794-3801	12.9	62

101	High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. <i>Gut</i> , <b>2017</b> , 66, 89-96	19.2	64
100	Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study. <i>Anti-Cancer Drugs</i> , <b>2017</b> , 28, 546-550	2.4	11
99	Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial. <i>Cancer</i> , <b>2017</b> , 123, 2752-2761	6.4	20
98	Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 2701-2708	7.5	50
97	Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. <i>Clinical Trials</i> , <b>2017</b> , 14, 451-461	2.2	38
96	Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. <i>Lancet HIV,the</i> , <b>2017</b> , 4, e486-e494	7.8	21
95	Diagnostic accuracy of the PROMIS study - AuthorsPreply. <i>Lancet, The</i> , <b>2017</b> , 390, 362	4.0	3
94	and Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2742-2749	12.9	29
93	Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 30.e9-30.e15	2.8	40
92	Treatment guidelines and early loss from care for people living with HIV in Cape Town, South Africa: A retrospective cohort study. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002434	11.6	13
91	The impact of the roll-out of rapid molecular diagnostic testing for tuberculosis on empirical treatment in Cape Town, South Africa. <i>Bulletin of the World Health Organization</i> , <b>2017</b> , 95, 554-563	8.2	20
90	Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial. <i>Antiviral Therapy</i> , <b>2017</b> , 22, 215-223	1.6	22
89	Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation. <i>International Journal of Epidemiology</i> , <b>2017</b> , 46, 728-744	7.8	15
88	The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2016</b> , 19, 258-63	6.2	7
87	Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort. <i>European Urology</i> , <b>2016</b> , 70, 668-674	10.2	45
86	Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease. <i>Human Molecular Genetics</i> , <b>2016</b> , 25, 2349-2359	5.6	27
85	Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 612-5	8.7	37
84	Common genetic variation and survival after colorectal cancer diagnosis: a genome-wide analysis. <i>Carcinogenesis</i> , <b>2016</b> , 37, 87-95	4.6	31

83	The Effects of Focal Therapy for Prostate Cancer on Sexual Function: A Combined Analysis of Three Prospective Trials. <i>European Urology</i> , <b>2016</b> , 69, 844-51	10.2	33
82	Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 266-72	8.7	39
81	Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 228-35	8.7	19
80	Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , <b>2016</b> , 387, 1066-1074	40	170
79	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 928-36	21.7	475
78	A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer. <i>Scientific Reports</i> , <b>2015</b> , 5, 10442	4.9	94
77	Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3453-61	12.9	22
76	Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study. <i>European Urology</i> , <b>2015</b> , 68, 927-36	10.2	126
75	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2392-8	10.3	22
74	The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update. <i>European Urology Focus</i> , <b>2015</b> , 1, 212-214	5.1	
73	Discordance between the results and conclusions of ICON7 - AuthorsPreply. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, e478-9	21.7	1
72	The FOCUS4 design for biomarker stratified trials. <i>Chinese Clinical Oncology</i> , <b>2015</b> , 4, 35	2.3	13
71	Response. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	
70	Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5322-30	12.9	379
69	Can we deliver randomized trials of focal therapy in prostate cancer?. <i>Nature Reviews Clinical Oncology</i> , <b>2014</b> , 11, 482-91	19.4	47
68	A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?. <i>British Journal of Cancer</i> , <b>2014</b> , 110, 2178-86	8.7	22
67	Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 631-9	21.7	81
66	Outcomes of a nurse-managed service for stable HIV-positive patients in a large South African public sector antiretroviral therapy programme. <i>Tropical Medicine and International Health</i> , <b>2014</b> , 19, 1029-39	2.3	24

65	Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5502-5502	2.2	54
64	Evaluating many treatments and biomarkers in oncology: a new design. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4562-8	2.2	105
63	Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1249-53	9.7	17
62	Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer. <i>Human Mutation</i> , <b>2013</b> , 34, 1026-34	4.7	44
61	Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer. <i>Human Molecular Genetics</i> , <b>2013</b> , 22, 825-31	5.6	49
60	Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 4104-13	12.9	72
59	Increasing transfers-out from an antiretroviral treatment service in South Africa: patient characteristics and rates of virological non-suppression. <i>PLoS ONE</i> , <b>2013</b> , 8, e57907	3.7	19
58	Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 622-32	21.7	292
57	Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , <b>2012</b> , 38, 618-25	14.4	85
56	Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. <i>British Journal of Cancer</i> , <b>2012</b> , 107, 1037-43	8.7	33
55	The Royal College of Physicians Simms Lecture, 6 December 2011: clinical research networks and the benefits of intensive healthcare systems. <i>Clinical Medicine</i> , <b>2012</b> , 12, 446-52	1.9	5
54	Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 642-53	21.7	200
53	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. <i>Lancet, The</i> , <b>2011</b> , 377, 2103-14	40	762
52	Strengthening clinical cancer research in the United Kingdom. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 1529-34	3.7	31
51	Mother-to-child transmission of HIV in a community-based antiretroviral clinic in South Africa. <i>South African Medical Journal</i> , <b>2010</b> , 100, 827-31	1.5	23
50	Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e275-6; author reply e277-8	2.2	11
49	Improving cancer outcomes through international collaboration in academic cancer treatment trials. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5109-14	2.2	42
48	Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. <i>British Journal of Cancer</i> , <b>2009</b> , 100, 251-8	8.7	56



47	Speeding up the evaluation of new agents in cancer. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 1204-14	9.7	109
46	How can we improve clinical trials?. <i>Nature Clinical Practice Oncology</i> , <b>2007</b> , 4, 206-7		2
45	Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 4899-907	12.9	361
44	Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 3354-60	2.2	158
43	GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. <i>Neuro-Oncology</i> , <b>2005</b> , 7, 425-34	1	26
42	A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. <i>Molecular Therapy</i> , <b>2004</b> , 10, 958-66	11.7	332
41	Issues in regulatory guidelines for data monitoring committees. <i>Clinical Trials</i> , <b>2004</b> , 1, 162-9	2.2	17
40	Participation of patients 65 years of age or older in cancer clinical trials. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 1383-9	2.2	800
39	Incremental treatment costs in national cancer institute-sponsored clinical trials. <i>JAMA - Journal of the American Medical Association</i> , <b>2003</b> , 289, 2970-7	27.4	57
38	Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 2508-18	2.2	330
37	Patterns of care for the treatment of bladder cancer. <i>Journal of Urology</i> , <b>2003</b> , 169, 1697-701	2.5	70
36	Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 1192-202	2.2	236
35	The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. <i>Cancer</i> , <b>2002</b> , 95, 1504-10	6.4	251
34	How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2109-17	2.2	394
33	Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2277-83	2.2	156
32	Cancer Molecular Analysis Project: weaving a rich cancer research tapestry. <i>Cancer Cell</i> , <b>2002</b> , 1, 315-8	24.3	20
31	Measuring the incremental cost of clinical cancer research. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 105-10	2.2	24
30	Clinical trial designs for cytostatic agents. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 3154-5	2.2	24

29	Clinical trial designs for cytostatic agents: are new approaches needed?. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 265-72	2.2	288
28	Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 708-15	2.2	377
27	New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 205-16	9.7	13624
26	Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2000</b> , 124, 995-1000	5	201
25	Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 3461-7	2.2	839
24	Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 1017-24	9.7	473
23	Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. <i>Journal of the National Cancer Institute</i> , <b>1999</b> , 91, 1382-90	9.7	375
22	National Cancer Institute Clinical Trials Program in Colorectal Cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1998</b> , 42 Suppl, S75-9	3.5	12
21	Complexities, pitfalls, and strategies for evaluating brain tumor therapies. <i>Current Opinion in Oncology</i> , <b>1998</b> , 10, 175-8	4.2	13
20	The American press and political community: reporting in Detroit 1865-1920. <i>Media, Culture and Society</i> , <b>1997</b> , 19, 331-355	2.5	5
19	Effect of back supports on back strength in patients with osteoporosis: a pilot study. <i>Mayo Clinic Proceedings</i> , <b>1996</b> , 71, 235-41	6.4	44
18	The National Cancer Institute audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-06. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 1469-74	59.2	59
17	Transient traumatic quadriplegia in a 29-year-old man without predisposing anatomic lesion. <i>Archives of Physical Medicine and Rehabilitation</i> , <b>1995</b> , 76, 1006-10	2.8	1
16	Long-term survival in patients with malignant astrocytoma. <i>Neurosurgery</i> , <b>1994</b> , 34, 213-9; discussion 219-20	3.2	109
15	Long-Term Survival in Patients with Malignant Astrocytoma. <i>Neurosurgery</i> , <b>1994</b> , 34, 213-220	3.2	4
14	Posture Training Support: preliminary report on a series of patients with diminished symptomatic complications of osteoporosis. <i>Mayo Clinic Proceedings</i> , <b>1993</b> , 68, 1171-6	6.4	24
13	Supratentorial malignant gliomas: risk patterns and therapy. <i>Journal of the National Cancer Institute</i> , <b>1993</b> , 85, 690-1	9.7	26
12	Neoadjuvant therapy in cancer treatment. <i>Cancer</i> , <b>1993</b> , 72, 3515-24	6.4	31

11	A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. <i>Journal of Clinical Oncology</i> , <b>1988</b> , 6, 1732-5	2.2	95
10	Monocyte-derived growth factors for human tumor clonogenic cells. <i>Journal of Leukocyte Biology</i> , <b>1986</b> , 40, 381-92	6.5	13
9	Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. <i>Cancer</i> , <b>1986</b> , 57, 1866-70	6.4	175
8	Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1986</b> , 18, 33-8	3.5	12
7	Expanded role of the cerebrospinal fluid reservoir in neurooncology: indications, causes of revision, and complications. <i>Neurosurgery</i> , <b>1985</b> , 17, 600-3	3.2	22
6	Brain-blood barrier? Yes and no. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1983</b> , 80, 7352-6	11.5	84
5	Morphologic effect of dimethyl sulfoxide on the blood-brain barrier. <i>Science</i> , <b>1982</b> , 217, 164-6	33.3	120
4	Effect of age and reoperation on survival in the combined modality treatment of malignant astrocytoma. <i>Neurosurgery</i> , <b>1982</b> , 10, 454-63	3.2	91
3	Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide. <i>Clinical Pharmacology and Therapeutics</i> , <b>1982</b> , 32, 122-8	6.1	24
2	Diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone, plasma and cerebrospinal fluid kinetics. <i>Clinical Pharmacology and Therapeutics</i> , <b>1982</b> , 31, 650-5	6.1	17
1	Initial levels of CEA and their rate of change in pancreatic carcinoma following surgery chemotherapy and radiation therapy. <i>Cancer</i> , <b>1978</b> , 42, 1472-6	6.4	21